Menlo Park, United States
Doloromics, founded in 2020, is at the forefront of biotechnological innovation in the United States. Operating within the Biotechnology and Health Care sectors, the company is committed to developing precision medicines aimed at conquering chronic pain, as reflected in its slogan: "Doloromics is developing precision medicines to conquer chronic pain".
With a focus on Health and Wellness, Doloromics has captured the interest of investors, securing a substantial $6.67M Seed Round investment on 01 February 2022. This funding round was led by the esteemed Mayfield Fund, which underscores the company's potential and the growing demand for innovative pain management solutions.
As the company advances, it stands poised to make significant inroads into the field of chronic pain treatment, promising impactful solutions that address a large, unmet medical need. Doloromics represents a promising investment opportunity due to its early-stage momentum and strategic focus.
